DTIC ADA476032: Alpha v Integrin Targeted PET pdf

DTIC ADA476032: Alpha v Integrin Targeted PET

More Book Details

Description of the Book:

The overall objective of this project is to develop 18F-labeled RGD peptide derivatives for breast cancer imaging with prolonged tumor retention and improved in vivo kinetics to visualize and quantify alpha v-integrin expression and subsequently evaluate the metronomic anti-angiogenic chemotherapy efficacy on tumor regression necrosis and angiogenesis. Specific Aims: (1) To optimize 18F-labeled RGD peptide tracer for breast cancer imaging with prolonged tumor retention and improved in vivo kinetics. (2) To demonstrate the feasibility of PET/18F-RGD to image breast tumor growth spread and angiogenesis as well as quantifying alpha v-integrin expression level during breast tumor neovascularization over time. (3) To evaluate the efficacy of EMD 121974/paclitaxel combination on tumor regression necrosis and angiogenesis and demonstrate the feasibility of PET/18F-RGD to monitor the treatment outcomes. Major findings: We have developed a series of novel multimeric RGD peptides for PET imaging. We have also successfully demonstrated that suitably labeled RGD peptide allows quantification of integrin expression in vivo in a non-invasive manner.

We have also synthesized a RGD-paclitaxel conjugate for breast cancer integrin targeted therapy

• Creator/s: Defense Technical Information Center
• Date: 8/1/2007
• Year: 2007
• Book Topics/Themes: DTIC Archive, Chen, Xiaoyuan, STANFORD UNIV CA SCHOOL OF MEDICINE, *NECROSIS, *RADIOCHEMISTRY, *BREAST CANCER, *ANGIOGENESIS, PEPTIDES, CLINICAL MEDICINE, KINETICS, CHEMICAL DERIVATIVES, IN VIVO ANALYSIS, RETENTION(PSYCHOLOGY), CHEMOTHERAPY

An excerpt captured from the PDF book